FGFR3 and urinary bladder cancer: FGFR3 was observed to efficiently detect bladder cancer in patients with low grade tumors [50] whereas NMP-22 (unspecified test platform) and BTAstat were shown to outperform cytology in detecting G3 tumors, with the former also showing significantly higher detection rates for G1 and G2 tumors [58].